Mesenchymal Stromal Cells Used for Cellular Cardiomyoplasty As a Way To Treat Myocardial Infarction and Heart Failure
DOI:
https://doi.org/10.47611/jsrhs.v10i3.1917Keywords:
myocardial infarction, heart failure, cellular cardiomyoplasty, mesenchymal stromal cells, mesenchymal stem cellsAbstract
Heart disease is one of the leading causes of morbidity and mortality worldwide. Two of these diseases are heart failure and myocardial infarction. In America alone, there are about 6.2 million people with heart failure, and every 40 seconds, a patient with a heart attack is recorded. Myocardial infarction, known as a heart attack, occurs after the blocking or occlusion of a coronary artery, disabling the delivery of oxygenated blood to regions of the heart. Heart failure, usually occurring after ischemic diseases like myocardial infarction, is where the heart loses the ability to pump a sufficient blood supply to meet the body’s needs. The major ways of treating heart failure and myocardial infarction today are either too expensive or hard to come by, so a new sort of treatment is direly needed. Cellular cardiomyoplasty, a form of cell therapy, is being looked into as a new way to treat these two and other cardiomyopathies. Additionally, though there have been a few cells that have shown a possibility of use for cardiomyoplasty, this review focuses on mesenchymal stem cells, specifically called mesenchymal stromal cells. The purpose of this review is to look into what cellular cardiomyoplasty is, how it may be used in the future, and how mesenchymal stromal cells have shown potential to be used for it.
Downloads
References or Bibliography
Leri, A., Rota, M., Pasqualini, F. S., Goichberg, P., & Anversa, P. (2015,
January 2). Origin of Cardiomyocytes in Adult Heart. PubMed Center. Retrieved September 30, 2020, from
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4283577/#!po=0.847458
Domenech, M., Polo-Corrales, L., Ramirez-Vick, J. E., & Freytes, D. O. (2016,
December 1). Tissue Engineering Strategies for Myocardial Regeneration:
Acellular Versus Cellular Scaffolds? PubMed Central. Retrieved September
, 2020, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5124749/#s001title
Heallen, T. R., Kadow, Z. A., Kim, J. H., Wang, J., & Martin, J. F. (2019, May
. Stimulating Cardiogenesis as a Treatment for Heart Failure.
Circulation Research. Retrieved September 30, 2020, from
https://www.ahajournals.org/doi/full/10.1161/CIRCRESAHA.118.313573
Piano, M. R., & Carrigan, T. M. (2003, December). Cellular Cardiomyoplasty A New
Therapeutic Approach for Regenerating the Myocardium. NursingCenter.
Retrieved September 30, 2020, from https://www.nursingcenter.com/journalarticle?Article_ID=447333&Journal_ID=54006&Issue_ID=447308 .
Pendyala, L., Gadesam, R., Ghiu, I., Hou, D., & Chronos, N. (2008, June 19).
Cellular Cardiomyoplasty and Cardiac Regeneration. CathLabDigest.
Retrieved October 1, 2020, from https://www.cathlabdigest.com/articles/Cellular-Cardiomyoplasty-and-Cardiac-Regeneration
Deaths from Heart Failure Vary by Geography. (n.d.). Centers for Disease Control
and Prevention. Retrieved October 1, 2020, from https://www.cdc.gov/heartdisease/heart_failure.htm
Heart Failure. (n.d.). National Heart, Lung, and Blood Institute. Retrieved
October 1, 2020, from https://www.nhlbi.nih.gov/health-topics/heart-failure
Heart Attack (Myocardial Infarction). (2019, February). Harvard Health
Publishing. Retrieved October 1, 2020, from https://www.health.harvard.edu/a_to_z/heart-attack-myocardial-infarction-a-to-z
Thygesen, K., Alpert, J. S., & White, H. D. (2007, October 19). Universal
Definition of Myocardial Infarction. Circulation. Retrieved October 1, 2020, from https://www.ahajournals.org/doi/full/10.1161/circulationaha.107.187397
Bayés-Genis, A. (2020, April 24). Heart Failure Treatment by Device. PubMed
Central. Retrieved October 1, 2020, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7199188/
Medications Used to Treat Heart Failure. American Heart Association. Retrieved October 1, 2020,
Mayo Clinic Staff. (n.d.). Heart Disease. Mayo Clinic. Retrieved October 1,
, from https://www.mayoclinic.org/diseases-conditions/heart-disease/symptoms-causes/syc-20353118
Lo, B., & Parham, L. (2009, April 14). Ethical Issues in Stem Cell Research.
Retrieved October 2, 2020, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726839/#__sec5title
FDA Warns About Stem Cell Therapies. (2019, September 3). FDA. Retrieved October
, 2020, from https://www.fda.gov/consumers/consumer-updates/fda-warns-about-stem-cell-therapies
Stem cells to repair heart damage? Not so fast. (2018, January). Harvard Health
Publishing. Retrieved October 3, 2020, from https://www.health.harvard.edu/heart-health/stem-cells-to-repair-heart-damage-not-so-fast
Heart Attack Symptoms, Risk, and Recovery. (n.d.). Center for Disease Control
and Prevention. Retrieved October 7, 2020, from https://www.cdc.gov/heartdisease/heart_attack.htm
Pendyala, L., Goodchild, T., Gadesam, R. R., Chem, J., Robinson, K., Chronos,
N., & Hou, D. (2008, May 4). Cellular Cardiomyoplasty and Cardiac Regeneration. PubMed Central. Retrieved October 7, 2020, from
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2779354/
Dorin, R. P., & Koh, C. J. (2011). Cellular Cardiomyoplasty. Science Direct. Retrieved October 7, 2020, from https://www.sciencedirect.com/topics/agricultural-and-biological-sciences/cellular-cardiomyoplasty
Prifti, E., Lascio, G., Harmelin, G., Bani, D., Briganti, V., Veshti, A., & Bonacchi, M. (2016, February 13). Cellular cardiomyoplasty into infracted swine's hearts by retrograde infusion through the venous coronary sinus: An experimental study. Retrieved November 06, 2020, from https://www.sciencedirect.com/science/article/pii/S1553838916300185
Steele, A., Paulsen, M., Wang, H., Stapleton, L., Lucian, H., Eskandari, A., Hironaka, C. E., Farry, J. M., Baker, S. W., Thakore, A. D., Jaatinen, K. J., Tada, Y., Hollander, M. J., Williams, K. M., Seymour, A. J., Totherow, K. P., Yu, A. C., Cochran, J. R., Woo, Y. (2020, January 21). Multi-phase catheter-injectable hydrogel enables dual-stage protein-engineered cytokine release to mitigate adverse left ventricular remodeling following myocardial infarction in a small animal model and a large animal model. Retrieved November 06, 2020, from https://www.sciencedirect.com/science/article/abs/pii/S104346661930403X
Thornton, A. J., Alsberg, E., Albertelli, M., & Moone, D. J. (2004). Shape-defining scaffolds for minimally invasive tissue engineering. Microsoft Academic. Retrieved November 06, 2020, from https://academic.microsoft.com/search?q=shape+defining+scaffolds+for+minimally+invasive+tissue+engineering+catheter+delivery+procedure
Dah-Ching Ding, W. (2011, February 1). Mesenchymal Stem Cells - Dah-Ching Ding, Woei-Cherng Shyu, Shinn-Zong Lin, 2011. PubMed. Retrieved November 06, 2020, from https://journals.sagepub.com/doi/full/10.3727/096368910X
Division of Pulmonary and Critical Care Medicine, Dakhlallah, D., Zhang, J., Yu, L., Marsh, C., Angelos, M. G., & MPharm, M. (n.d.). MicroRNA-133a Engineered Mesenchymal Stem Cells Augment... : Journal of Cardiovascular Pharmacology. PubMed. Retrieved November 06, 2020, from https://pubmed.ncbi.nlm.nih.gov/25658461/
Gathier, W., Van Ginkel, D., Van der Naald, M., Van Slochteren, F., Doevendans, P., & Chamuleau, S. (2018, February 1). Retrograde Coronary Venous Infusion as a Delivery Strategy in Regenerative Cardiac Therapy: An Overview of Preclinical and Clinical Data. PubMed. Retrieved November 06, 2020, from https://www.ncbi.nlm.nih.gov/pubmed/29392536
Naji, A., Eitoku, M., Favier, B. et al. (2019) Biological functions of mesenchymal stem cells and clinical implications. Springer Link. https://doi.org/10.1007/s00018-019-03125-1
Louis A. Cona, M. (2020, July 17). What are Mesenchymal Stem Cells (MSCs)? Retrieved November 06, 2020, from https://www.dvcstem.com/post/what-are-mesenchymal-stem-cells
Guo, Y., Yu, Y., Hu, S., Chen, Y., & Shen, Z. (2020, May 11). The therapeutic potential of mesenchymal stem cells for cardiovascular diseases. Retrieved November 06, 2020, from https://www.nature.com/articles/s41419-020-2542-9
Ong, S., Hernández-Reséndiz, S., Crespo-Avilan, G., Mukhametshina, R., Kwek, X., Cabrera-Fuentes, H., & Hausenloy, D. (2018, June). Inflammation following acute myocardial infarction: Multiple players, dynamic roles, and novel therapeutic opportunities. PubMed. Retrieved November 06, 2020, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5981007/
Galie, P. A., & Stegemann, J. P. (2014, July 16). Injection of mesenchymal stromal cells into a mechanically stimulated in vitro model of cardiac fibrosis has paracrine effects on resident fibroblasts. PubMed. Retrieved November 06, 2020, from https://pubmed.ncbi.nlm.nih.gov/24713331/
Simeoni, R., Francisco, J. C., Miyague, N., Irioda, A. C., Souza, C. M., Souza, D., et al. (2020, October 28). Beneficial Roles of Cellulose Patch-Mediated Cell Therapy In Myocardial Infarction: A Preclinical Study. Retrieved November 06, 2020, from https://www.preprints.org/manuscript/202010.0573/v1
EJ. Benjamin, M., P. Ponikowski, A., D. Orlic, J., LH. Lund, L., MG. St John Sutton, N., Jugdutt, B., et al. (2020, August 12). Stem Cell Therapy for Chronic and Advanced Heart Failure. Springer Link. Retrieved November 06, 2020, from https://link.springer.com/article/10.1007/s11897-020-00477-9
Fathy WM, NourEldin RI, Shalby GH. (2019). Differentiation of umbilical cord Wharton's jelly derived mesenchymal stem cells into cardiomyocytes using 5-azacytidine. Menoufia Med J http://mmj.eg.net/article.asp?issn=1110-2098;year=2019;volume=32;issue=3;spage=991;epage=995;aulast=Fathy
Gorjipour, F., Hosseini-Gohari, L., Alizadeh Ghavidel, A., Hajimiresmaiel, S., Naderi, N., Darbandi Azar, A., & Pazoki-Toroudi, H. (2019, February 25). Mesenchymal stem cells from human amniotic membrane differentiate into cardiomyocytes and endothelial-like cells without improving cardiac function after surgical administration in rat model of chronic heart failure. PubMed. Retrieved November 08, 2020, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6477105/
Nursalim, A., Katili, P., & Santoso, T. (2016). Cellular Cardiomyoplasty For Myocardial Infarction: A 2014 Evidence-based Update. Acta Medica Indonesia. Retrieved November 08, 2020, from http://actamedindones.org/index.php/ijim/article/view/83
Gabisonia, K., Prosdocimo, G., Aquaro, G.D. et al. (2019) MicroRNA therapy stimulates uncontrolled cardiac repair after myocardial infarction in pigs. Nature 569, 418–422 https://doi.org/10.1038/s41586-019-1191-6
Rieckmann, M., Delgobo, M., Gaal, C., Büchner, L., Steinau, P., Reshef, D., et al. (2019, August 13). Myocardial infarction triggers cardioprotective antigen-specific T helper cell responses. J Clin Invest. 2019;129(11):4922-4936. Retrieved November 09, 2020, from https://www.jci.org/articles/view/123859
Chapman, A., Shah, A., Lee, K., Anand, A., Francis, O., Adamson, P., et al. (2017, November 17). Long-Term Outcomes in Patients With Type 2 Myocardial Infarction and Myocardial Injury. Circulation, 137(12),1236–1245. Retrieved November 09, 2020, from https://www.ahajournals.org/doi/full/10.1161/circulationaha.117.031806
Bacmeister, L., Schwarzl, M., Warnke, S. et al. (2019). Inflammation and fibrosis in murine models of heart failure. Basic Res Cardiol 114(19) https://doi.org/10.1007/s00395-019-0722-5
C. Loebel, J., Mahla, R., A. Polymeri, W., N. D'Souza, F., TS. Windt, L., A. Singh, A., et al. (2020, March 05). Characterization of the immunomodulatory properties of alveolar bone-derived mesenchymal stem cells. Stem Cell Research & Therapy, 11,102. Retrieved November 10, 2020, from https://link.springer.com/article/10.1186/s13287-020-01605-x
Caplan, A., AJ. Friedenstein, J., AJ. Friedenstein, S., AJ. Friedenstein, R., AJ. Friedenstein, R., AJ. Friedenstein, R., et al. (2020, August 08). Mesenchymal stromal cell therapies: Immunomodulatory properties and clinical progress. Stem Cell Research and Therapy, 11(345) Retrieved November 10, 2020, from https://stemcellres.biomedcentral.com/articles/10.1186/s13287-020-01855-9
Published
How to Cite
Issue
Section
Copyright (c) 2021 Amarachukwu Okpala; Leya Joykutty
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright holder(s) granted JSR a perpetual, non-exclusive license to distriute & display this article.
